Conte P, Bisagni G, Piacentini F, Sarti S, et al. Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial. J Clin Oncol 2023 Sep 25:JCO2300790. doi: 10.1200/JCO.23.00790.
PMID: 37748109